Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in PAH 2017-03-03T15:51:33+00:00

Clinical Trials

January 22, 2013

A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endotherlial Dysfunction in Pulmonary Arterial Hypertension

  • Study Sponsor: National Institutes of Health
  • Start Date: 01/2013
  • End Date: 01/2016
  • Design: Placebo-controlled (Randomized), background treatment allowed
  • Age range (years): from 18 to 99
  • Type of PH
    • All PAH (Group 1 PH)
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • CHD – APAH
    • PoPH – APAH
    • Toxic – APAH
    • HIV – APAH
    • Hem – APAH
  • Study Duration for individual patient: 24 weeks
  • Contact: Bonnie Harper at PAHresearch@nih.gov
  • Listing on clinicaltrials.gov